VRTX Vertex Pharma scored a $612 target from Morgan Stanley's Terence Flynn today. The $596 prior mark jumped $16 showing analyst conviction in the $145B biotech. The firm maintained its buy rating.
REGN Regeneron grabbed a similar boost from Morgan Stanley. Matthew Harrison lifted his target to $796 from $769 maintaining hold. The $94B drugmaker held analyst attention despite sector rotation pressure.
Energy names saw mixed activity. FANG Diamondback Energy climbed to $245 from $240 per UBS analyst Josh Silverstein. The shale producer benefited from oil above $100 amid Iran conflict. CVX Chevron consensus target rose to $206 from $204 showing modest energy optimism.
Cruise operators faced downgrades. RCL Royal Caribbean absorbed a Barclays cut to $351 from $361 despite maintaining buy. NCLH Norwegian Cruise fell to $21 from $22 at hold as travel demand questions persisted.
AVGO Broadcom consensus climbed to $473 from $472. MSFT Microsoft slipped to $585 from $587 showing tech target compression. Pharma conviction contrasted with tech caution.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
